Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention

Chinese Medical Journal

Volumn 124, Issue 6, 2011, Pages 856-861

  Ren, Yi Hong ^a   Zhao, Ming ^a   Chen, Yun Dai ^a   Chen, Lian ^a   Liu, Hong Bin ^a   Wang, Yu ^a   Sun, Zhi Jun ^a   Chen, Jin Song ^a   Huang, Ting Ting ^a   Guo, Yu Song ^a   Xie, Yong Jin ^a   Wang, Chun Ya ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Acute coronary syndrome; Clopidogrel; Omeprazaole; Platelet activation; Thrombelastography mapping

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; OMEPRAZOLE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK POPULATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 79952842906     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.06.010     Document Type: Article

References (29)

1. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27: 647-654.
2. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
3. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101:
4. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718.
5. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
6. Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 699-700.
7. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of Omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008; 51: 256-260.
8. Possible "class effect" for proton-pump inhibitors on top of clopidogrel therapy. 2009. (Accessed at May 6, 2009 at http://www.theheart.org/article/967075.do)
9. Dunn SP, Macaulay TE, Brennan DM. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008; 118: 815A.
10. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007; 116: 2923-2932.
11. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
12. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med 2010; 363: 1909-1917.
13. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
14. Craft RM, Chavez JJ, Bresee SJ, Wortham DC, Cohen E, Carroll RC. A novel modification of the Thrombelastograph ssay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143: 301-309.
15. Hobson AR, Agarwala RA, Swallow RA, Dawkins KD, Curzen NP. Thrombelastography: current clinical applications and its potential role in interventional cardiology. Platelets 2006; 17: 509-518.
16. Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol 2009; 104: 227-233.
17. Ren YH, Wang HY, Wang CY, Wang Y, Yang TS, Gai LY, et al. The comparative study of modified TEG graphy and flow cytometry about the effects of tirofiban on ACS. Chin J Cardiol (Chin) 2007; 35: 366-367.
18. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754-762.
19. Nainggolan L. Un-POPULAR? Utility of platelet-function tests "modest". (Accessed February 23, 2010 at http://www.theheart.org/article/1049535.do)
20. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
21. Katori N, Szlam F, Levy JH, Tanaka KA. A novel method to assess platelet inhibition by eptifibatide with thrombelastograph. Anesth Analg 2004; 99: 1794-1799.
22. Ren YH, Wang HY, Wang CY, Wang Y, Yang TS, Gai LY, et al. Evaluation of triple anti-platelet therapy by modified thrombelastography in patients with acute coronary syndrome. Chin Med J 2008; 121: 850-852.
23. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
24. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-666.
25. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
26. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Alimentary Pharmacol Ther 2010; 31: 810-823.
27. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718.
28. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004; 76: 201-209.
29. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 119-125.